Inside-Out of Complement in Cancer.

biomarkers cancer complosome extracellular complement intracellular complement therapy tumor microenvironment

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 28 04 2022
accepted: 06 06 2022
entrez: 21 7 2022
pubmed: 22 7 2022
medline: 23 7 2022
Statut: epublish

Résumé

The role of complement in cancer has received increasing attention over the last decade. Recent studies provide compelling evidence that complement accelerates cancer progression. Despite the pivotal role of complement in fighting microbes, complement seems to suppress antitumor immunity

Identifiants

pubmed: 35860237
doi: 10.3389/fimmu.2022.931273
pmc: PMC9291441
doi:

Substances chimiques

Complement System Proteins 9007-36-7

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

931273

Informations de copyright

Copyright © 2022 Kolev, Das, Gerber, Baver, Deschatelets and Markiewski.

Déclaration de conflit d'intérêts

MK, MD, SB, MG and PD are employees and shareholders in Apellis Pharmaceuticals Inc., which actively develops drugs targeting the complement system. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Antibodies (Basel). 2020 Oct 25;9(4):
pubmed: 33113844
Cancer Res. 2019 Sep 15;79(18):4557-4566
pubmed: 31350295
Nature. 2019 Oct;574(7777):264-267
pubmed: 31578522
Nat Commun. 2018 Oct 10;9(1):4186
pubmed: 30305631
Semin Immunol. 2018 Jun;37:85-97
pubmed: 29454575
J Immunol. 2011 Feb 1;186(3):1840-8
pubmed: 21187443
J Immunol. 2016 Jun 1;196(11):4783-92
pubmed: 27183625
Oncogene. 2020 Mar;39(12):2612-2623
pubmed: 32020055
Trends Cancer. 2022 Jul;8(7):517-526
pubmed: 35288093
Mol Biotechnol. 2013 May;54(1):92-100
pubmed: 22565852
Pancreatology. 2013 May-Jun;13(3):290-7
pubmed: 23719603
J Exp Clin Cancer Res. 2020 Jan 13;39(1):9
pubmed: 31928530
Front Immunol. 2015 May 26;6:257
pubmed: 26074922
Mol Clin Oncol. 2018 Feb;8(2):315-319
pubmed: 29435296
Immunol Res. 2014 Aug;59(1-3):203-10
pubmed: 24906530
Autophagy. 2019 May;15(5):919-921
pubmed: 30741587
Diagnostics (Basel). 2020 Dec 11;10(12):
pubmed: 33322644
Nat Rev Immunol. 2018 Jan;18(1):5-18
pubmed: 28920587
Cancer Immunol Res. 2015 Dec;3(12):1325-32
pubmed: 26216416
Oral Dis. 2015 Oct;21(7):899-904
pubmed: 26258989
J Immunol. 1985 Mar;134(3):1804-9
pubmed: 3968432
Breast Cancer Res. 2014 Jun 16;16(3):R63
pubmed: 24935269
Leukemia. 2015 Feb;29(2):406-14
pubmed: 24903480
Int J Mol Sci. 2020 Jan 17;21(2):
pubmed: 31963450
Cancer Discov. 2018 Sep;8(9):1142-1155
pubmed: 29884728
Science. 2014 Mar 14;343(6176):1260-3
pubmed: 24626930
Mol Immunol. 2019 Oct;114:341-352
pubmed: 31446305
Nat Rev Nephrol. 2018 Jan;14(1):26-47
pubmed: 29199277
Front Immunol. 2018 Sep 25;9:2203
pubmed: 30319647
Anal Chem. 2019 Oct 1;91(19):12435-12443
pubmed: 31453685
Drugs. 2015 May;75(8):923-7
pubmed: 25940913
Immunity. 2021 May 11;54(5):1002-1021.e10
pubmed: 33761330
Cell Rep. 2014 Mar 27;6(6):1085-1095
pubmed: 24613353
Am J Transl Res. 2014 Jan 15;6(2):114-8
pubmed: 24489990
J Biol Chem. 2016 Jul 15;291(29):14927-38
pubmed: 27226542
Cancer Cell. 2018 Oct 8;34(4):561-578.e6
pubmed: 30300579
Front Immunol. 2014 Oct 20;5:520
pubmed: 25368619
Cell. 2015 Feb 12;160(4):700-714
pubmed: 25679762
Semin Cell Dev Biol. 2019 Jan;85:153-163
pubmed: 29155219
J Natl Cancer Inst. 2013 Sep 18;105(18):1385-93
pubmed: 23940286
Exp Cell Res. 2018 May 15;366(2):127-138
pubmed: 29551360
J Immunol. 2004 Aug 15;173(4):2524-9
pubmed: 15294968
Adv Exp Med Biol. 2014;772:229-62
pubmed: 24272362
Cell Rep. 2020 May 19;31(7):107628
pubmed: 32433953
Front Immunol. 2021 Feb 25;12:629986
pubmed: 33717157
Sci Immunol. 2021 Dec 24;6(66):eabf2489
pubmed: 34932384
Clin Cancer Res. 2010 Jun 15;16(12):3226-31
pubmed: 20515868
Oncol Rep. 2009 Jun;21(6):1405-11
pubmed: 19424617
Nat Rev Nephrol. 2016 Jul;12(7):383-401
pubmed: 27211870
J Extracell Vesicles. 2020 Nov;10(1):e12031
pubmed: 33708358
Nat Immunol. 2008 Nov;9(11):1225-35
pubmed: 18820683
Br J Cancer. 2016 Oct 11;115(8):949-956
pubmed: 27657339
Front Immunol. 2019 Apr 03;10:672
pubmed: 31001274
Mol Immunol. 2014 Oct;61(2):56-8
pubmed: 25081089
J Invest Dermatol. 2021 Feb;141(2):404-414.e6
pubmed: 32682912
Front Immunol. 2018 Jul 16;9:1629
pubmed: 30061895
Front Immunol. 2015 Jun 02;6:262
pubmed: 26082779
J Neuroimmunol. 2015 Jan 15;278:271-6
pubmed: 25468776
Cancer Immunol Res. 2019 Jul;7(7):1091-1105
pubmed: 31164356
Immunity. 2015 Jun 16;42(6):1033-47
pubmed: 26084023
Int J Mol Sci. 2020 Apr 17;21(8):
pubmed: 32316695
Biochem J. 1998 Feb 15;330 ( Pt 1):163-8
pubmed: 9461505
Front Immunol. 2017 Oct 04;8:1245
pubmed: 29046676
Sci Rep. 2020 Oct 27;10(1):18400
pubmed: 33110136
Cancer Immunol Res. 2021 Dec;9(12):1383-1399
pubmed: 34667108
Eur J Cancer. 2018 Sep;100:17-26
pubmed: 29936063
Cancer Immunol Res. 2021 Jan;9(1):113-122
pubmed: 33177111
Mol Immunol. 2017 Sep;89:2-9
pubmed: 28601357
Science. 2018 May 4;360(6388):558-563
pubmed: 29724957
Immunol Rev. 2020 May;295(1):68-81
pubmed: 32166778
Annu Rev Immunol. 2018 Apr 26;36:309-338
pubmed: 29677470
Semin Nephrol. 2013 Nov;33(6):479-92
pubmed: 24161035
Cancer Discov. 2017 Jul;7(7):694-703
pubmed: 28288993
Nat Rev Immunol. 2014 Dec;14(12):811-20
pubmed: 25394942
Front Oncol. 2021 Feb 15;10:617890
pubmed: 33732636
Immunity. 2013 Dec 12;39(6):1143-57
pubmed: 24315997
J Clin Invest. 2017 Mar 1;127(3):970-981
pubmed: 28192370
Cancer Immunol Res. 2021 Aug;9(8):891-908
pubmed: 34039653
Mol Cancer. 2010 Jun 07;9:139
pubmed: 20529262
J Immunol. 2020 Dec 1;205(11):3218-3229
pubmed: 33158953
BMC Cancer. 2021 Oct 23;21(1):1135
pubmed: 34688260
Cell Metab. 2017 Jul 5;26(1):49-70
pubmed: 28683294
Nat Cancer. 2021 Feb;2(2):218-232
pubmed: 34505065
J Immunol. 2013 Jun 15;190(12):5921-5
pubmed: 23690475
J Exp Clin Cancer Res. 2020 Jan 13;39(1):11
pubmed: 31931851
J Cell Mol Med. 2019 May;23(5):3097-3107
pubmed: 30825266
Cancer Biol Med. 2021 May 07;:
pubmed: 33960177
Nat Rev Drug Discov. 2019 Sep;18(9):707-729
pubmed: 31324874
Front Immunol. 2013 Jan 09;3:387
pubmed: 23316190
Leuk Res. 2008 Dec;32(12):1849-56
pubmed: 18584865
Sci Rep. 2021 Mar 3;11(1):5097
pubmed: 33658651
J Immunol. 1997 Aug 1;159(3):1429-36
pubmed: 9233640
N Engl J Med. 2021 Mar 18;384(11):1028-1037
pubmed: 33730455
Cell Rep. 2016 May 17;15(7):1505-1513
pubmed: 27160908
Nat Rev Cancer. 2019 Dec;19(12):698-715
pubmed: 31666715
Front Cell Dev Biol. 2021 Apr 01;9:657472
pubmed: 33869223
Science. 2016 Jun 17;352(6292):aad1210
pubmed: 27313051
Future Oncol. 2018 Apr;14(8):781-791
pubmed: 29521526
J Inflamm Res. 2016 Nov 16;9:209-219
pubmed: 27895507
Immunity. 2020 Mar 17;52(3):513-527.e8
pubmed: 32187519
Appl Immunohistochem Mol Morphol. 2011 Dec;19(6):540-6
pubmed: 21617523
Mol Immunol. 2003 Sep;40(2-4):109-23
pubmed: 12914817
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
Nature. 1989 Jun 22;339(6226):620-2
pubmed: 2733792
Cell Oncol (Dordr). 2021 Aug;44(4):937-950
pubmed: 34075561
Onco Targets Ther. 2020 Feb 18;13:1497-1505
pubmed: 32110047
Int J Mol Sci. 2021 Aug 09;22(16):
pubmed: 34445275
J Clin Invest. 2020 Aug 3;130(8):4039-4054
pubmed: 32369457
Br J Cancer. 2010 Jan 5;102(1):134-43
pubmed: 19920829
Clin Lab. 2020 Nov 1;66(11):
pubmed: 33180422
Signal Transduct Target Ther. 2021 Feb 26;6(1):86
pubmed: 33633112
J Immunol. 2017 Jan 15;198(2):788-797
pubmed: 27913632
Proc Natl Acad Sci U S A. 2020 Apr 14;117(15):8515-8523
pubmed: 32238563
Front Immunol. 2017 Jan 18;8:1
pubmed: 28149297
Lab Med. 2021 Nov 2;52(6):558-566
pubmed: 33929035
Front Immunol. 2019 Oct 04;10:2380
pubmed: 31636644
Cancer Immunol Res. 2021 Aug;9(8):909-925
pubmed: 34039652
Front Immunol. 2019 May 09;10:1054
pubmed: 31156630
Front Immunol. 2019 Apr 10;10:752
pubmed: 31024572
Cancer Immunol Res. 2019 Feb;7(2):193-207
pubmed: 30514794
J Proteome Res. 2014 Nov 7;13(11):4878-88
pubmed: 25057901
Medicina (Kaunas). 2021 Jan 21;57(2):
pubmed: 33494138
Immunobiology. 2019 Sep;224(5):625-631
pubmed: 31519376
Nat Immunol. 2010 Sep;11(9):862-71
pubmed: 20694009
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33789881
Cancer Manag Res. 2021 Sep 10;13:7131-7137
pubmed: 34531687
Cancer Metab. 2013 Jan 23;1(1):5
pubmed: 24280044

Auteurs

Martin Kolev (M)

Discovery, Apellis Pharmaceuticals, Waltham, MA, United States.

Madhumita Das (M)

Discovery, Apellis Pharmaceuticals, Waltham, MA, United States.

Monica Gerber (M)

Legal Department, Apellis Pharmaceuticals, Waltham, MA, United States.

Scott Baver (S)

Medical Affairs, Apellis Pharmaceuticals, Waltham, MA, United States.

Pascal Deschatelets (P)

Discovery, Apellis Pharmaceuticals, Waltham, MA, United States.

Maciej M Markiewski (MM)

Department of Immunotherapeutics and Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH